AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
AFOXOLANER; MILBEMYCIN OXIME
9 registrations across 2 African markets— 9 active
Markets with AFOXOLANER; MILBEMYCIN OXIME
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| NEXGARD SPECTRA TABLET; ORAL | 🇿🇼Zimbabwe | Boehringer Ingelheim Animal Health South Africa (Pty) Ltd | active | Dec 2027 |
| SECURGARD PLUS XL TABLETS | 🇬🇭Ghana | — | active | Apr 2027 |
| SECURGARD PLUS S TABLETS | 🇬🇭Ghana | — | active | Apr 2027 |
| SECURGARD PLUS XS TABLETS | 🇬🇭Ghana | — | active | Apr 2027 |
| SECURGARD PLUS M TABLETS | 🇬🇭Ghana | — | active | Apr 2027 |
| SECURGARD PLUS S TABLETS | 🇬🇭Ghana | — | active | Apr 2027 |
| SECURGARD PLUS M TABLETS | 🇬🇭Ghana | — | active | Apr 2027 |
| SECURGARD PLUS XS TABLETS | 🇬🇭Ghana | — | active | Apr 2027 |
| SECURGARD PLUS XL TABLETS | 🇬🇭Ghana | — | active | Apr 2027 |
AFOXOLANER; MILBEMYCIN OXIME in Africa — Regulatory Overview
AFOXOLANER; MILBEMYCIN OXIME is registered across 2 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Ghana, Zimbabwe. AfricaRegulatory refreshes this data daily from official government sources.
Of the 9 registrations, 9 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.